CYP2C8 polymorphism among the Portuguese

References

1. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol 1999; 13:289–95.10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-NSearch in Google Scholar

2. Fleming I. Cytochrome p450 and vascular homeostasis. Circ Res 2001; 89:753–62.10.1161/hh2101.099268Search in Google Scholar

3. Finta C, Zaphiropoulos PG. The human CYP2C locus: a prototype for intergenic and exon repetition splicing events. Genomics 2000; 63:433–8.10.1006/geno.1999.6063Search in Google Scholar

4. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5:895–931.10.1517/14622416.5.7.895Search in Google Scholar

5. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597–607.10.1097/00008571-200110000-00006Search in Google Scholar

6. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64:1579–89.10.1016/S0006-2952(02)01354-0Search in Google Scholar

7. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54:5543–6.Search in Google Scholar

8. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002; 300:399–407.10.1124/jpet.300.2.399Search in Google Scholar

9. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, et al. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 1999; 27:1260–6.Search in Google Scholar

10. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000; 28:1303–10.Search in Google Scholar

11. Borlak J, Walles M, Levsen K, Thum T. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos 2003; 31:888–91.10.1124/dmd.31.7.888Search in Google Scholar

12. Yun CH, Shimada T, Guengerich FP. Roles of human liver cytochrome P4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene. Cancer Res 1992; 52:1868–74.Search in Google Scholar

13. Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. J Hum Genet 2002; 47:605–10.10.1007/s100380200092Search in Google Scholar

14. Cavaco I, Stromberg-Norklit J, Kaneko A, Msellem MI, Dahoma M, Ribeiro VL, et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol 2005; 61:15–8.10.1007/s00228-004-0871-8Search in Google Scholar

15. Gardner MJ, Altman DG, editors. Statistics with confidence – confidence intervals and statistical guidelines. London: Br Med J 1989.Search in Google Scholar

16. Weise A, Grundler S, Zaumsegel D, Klotzek M, Grondahl B, Forst T, et al. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab 2004; 50:141–8.Search in Google Scholar

17. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76:119–27.10.1016/j.clpt.2004.04.006Search in Google Scholar

18. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U, et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299:25–8.10.1016/S0006-291X(02)02592-5Search in Google Scholar

19. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005; 77:468–78.10.1016/j.clpt.2005.01.018Search in Google Scholar PubMed

20. Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 2005; 61:491–7.10.1007/s00228-005-0938-1Search in Google Scholar PubMed

21. Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med 2003; 41:1345–50.10.1515/CCLM.2003.206Search in Google Scholar PubMed

22. Gil JP. Polymorphisms of the CYP2D6, GSTM1, GSTP1 and NAT2 in the Portuguese population – search for susceptibility markers in cancer pathologies. Ph.D. Dissertation Thesis, Universidade Nova de Lisboa, Portugal, 2000.Search in Google Scholar

23. Fleming I. Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol Res 2004; 49:525–33.10.1016/j.phrs.2003.11.016Search in Google Scholar PubMed

24. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, de Faire U, et al. Allelic variants of cytochrome P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003; 13:715–20.10.1097/00008571-200312000-00002Search in Google Scholar PubMed